NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Deficiency Analysis in On-Site Good Manufacturing Practice (GMP) Inspections of Manufacturers for Medicinal Products and Cosmetics by National Pharmaceutical Regulatory Agency (NPRA)

Kadar pengguna: 4 / 5

bintang aktifbintang aktifbintang aktifbintang aktifBintang tidak aktif
 

National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health as a secretariat of Drug Control Authority (DCA) is responsible to ensure the quality, safety and efficacy of registered products and notified cosmetics.

Good Manufacturing Practice (GMP) Section, Centre of Compliance and Quality Control is responsible to perform GMP inspection towards local and foreign manufacturing premise consists of:

  • Pharmaceutical products (including scheduled poisons, over the counter products and medicinal gases
  • Biologics products including Cell and Gene Therapy Products (CGTPs)
  • Traditional/herbal products
  • Health supplement products
  • Cosmetics

The pharmaceutical products, biologics products, traditional/herbal products and health supplements products are regulated as registered products. Hence, the manufacturers are required to apply for a manufacturing licence in order to conduct manufacturing activities. Meanwhile, cosmetics are regulated as notified products and do not require a manufacturing licence prior to manufacturing activities.

For CGTPs, it is regulated by NPRA under the listing programme until the year 2024 and the product requires full registration and manufacturing licence starting in 2025.

The study includes routine on-site inspections of local manufacturing facilities for pharmaceuticals, biologics, traditional/herbal medicines, health supplements, and cosmetics, non-routine on-site inspections of foreign pharmaceutical manufacturing facilities conducted between January to December 2023, excluding manufacturing premises of CGTPs as they are currently under NPRA's listing/voluntary registration program.

The purpose of the study is to analyse major and critical deficiencies observed during routine inspections of local manufacturers and non-routine inspections of foreign manufacturers, identify gaps between industry practices and regulatory expectations, and publish the analysis outcomes for industry reference.

To access the full report, please click here: Deficiencies Analysis Report 2023

Written by: Azraini Abdul Samat, Mohamad Khirul Anuar Mohd Noor, Meera Kumari Ram Navas, Noor Aini Zainal Abidin, Syafiqah Ab Jalil, Wong Kuan Yeen, Yah Xin Yun

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Jumaat 13 Disember 2024, 16:27:32.

Search

Menu Utama